U.S. Markets close in 3 hrs 47 mins

Seattle Genetics, Inc. (SGEN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
51.84-1.05 (-1.99%)
As of 12:11PM EDT. Market open.
People also watch
IMGNBMRNINCYALNYCLDX
  • A
    Anonymous
    Anonymous
    Any idea what the sell off is about?
    Kool
  • E
    ER
    ER
    Just saw this announcement from the Cancer Letter regarding ODAC's recommendation to approve use of Mylotarg, Pfizer's ADC targeted at CD33 that had been pulled from the US market in 2010 because of toxicity:

    The FDA Oncologic Drugs Advisory Committee July 11 voted to approve Pfizer’s Mylotarg (gemtuzumab ozogamicin, GO), a CD33-directed antibody-drug conjugate for the indication of “combination therapy with daunorubicin and cytarabine for the treatment of adult patients with previously untreated, de novo CD33-positive acute myeloid leukemia.

    Not sure what it might mean for SGEN's agent.
  • A
    Anonymous
    Anonymous
    For all who like Red live in Florida, god speed and best wishes for best outcome with Irma.
    May she die over water!
    Kool
  • C
    CPA-ADVISOR
    CPA-ADVISOR
    What the hay? 2 more insider sells outside of 15b plans. From cfo and evp of worldwide sales no less. If any buyout talk going on, obviously they are not involved.
  • A
    Anonymous
    Anonymous
    Genlab's update on the cervical cancer PI/II has been leaked out ahead of schedule I guess.
    Kool
  • t
    tom
    tom

    MICROCAP SPECIAL ALERT – BioLargo’s (BLGO) Surprise Acquisition of ENTIRE World Class Engineering Team from Fortune 500 CB&I Environmental & Infrastructure, Inc. Combined with New Financing Signals STRONG BUY as AOS Disruptive Water Treatment System Now Ready for $860 Billion Market

    BLGO COMMERCIAL REVENUES ARE STARTING NOW AND STRONGLY POSITIONED TO EXPLODE FOR YEARS TO COME

    Follow this chain of facts to understand the powerful investment implications:

    1. BLGO developed and owns the breakthrough AOS Water Treatment system that was just unveiled at the University of Alberta. The AOS is validated by many leading experts as the biggest breakthrough in water treatment in history

    2. The AOS system was validated by 1,600 studies and by the world’s largest water engineering company to disinfect and to also remove toxic contaminants better, faster and cheaper than all technologies

    3. Over 35 government grants support the AOS system

    4. After 10 years of development, the AOS system is now commercially ready for engineering to tailor and build it for user’s specific needs

    5. BLGO just acquired THE ENTIRE ENGINEERING INNOVATION TEAM THAT CREATED GIANT REVENUES FOR CB&I and now creates instant big revenues for BLGO

    6. The new engineering team brings substantial new business on day 1

    7. BLGO’S new Engineering and Science Division has powerful established business relationships with giant users for the AOS

    8. BLGO’s new Engineering & Science Division from CB&I is strongly incentivized to generate big and profitable revenues

    9. BLGO hired Dr Shan Yong as head of BD for the AOS. Dr Yong has long established relationships with Veolia and the world’s largest water companies

    10. BLGO just closed a finance commitment for $10 million with Lincoln Park Capital

    11. BLGO Clyra Medical division within days of filing 510k for novel low cost, best in class wound care products in a $10 billion market

    12. Clyra wound care products kill even resistant microbials (ESKAPE PATHOGENS) and promote healing

    13. 510k is a 90-day process

    14. Tanya Rhodes was head of wound care product development at giant Smith & Nephew

    15. Tanya Rhodes is now spearheading Clyra’s disruptive product entry into $10 billion market

    16. Several more proprietary blockbuster and disruptive wound care products are in pipeline

    17. CupriDyne industrial air treatment odor control is being sold now and is quickly being adopted by major companies

    18. 3 of the top 10 waste management companies have already signed National Purchasing Agreements and sales are increasing rapidly

    19. Word on the street is that CupiDyne is going to take over odor control

    20. CupriDyne sales potential is billions per year

    21. BLGO is destined to achieve enormous revenues and multi-billion dollar market cap in near term with major prolonged growth for years to come.

    https://finance.yahoo.com/news/biolargo-acquires-world-class-engineering-133000876.html

    BioLargo Acquires World-Class Engineering Team to Form a New Engineering Services Subsidiary and Enters into Common Stock Purchase Agreement for Up to $10 Million with Lincoln Park Capital
    Westminster, CA, Sept. 11, 2017-- BioLargo, Inc., a sustainable science and technology company that delivers practical solutions for clean water, clean air and advanced wound care, announced today it finalized ...
    finance.yahoo.com
  • D
    Diane
    Diane
    Juno's got it going on!
  • A
    Anonymous
    Anonymous
    Polatuzumab Vedotin received Prime designation from EMA on June 30, 2017
  • r
    ron
    ron
    Jumping today! 💰🎉
    Any news?
  • C
    CPA-ADVISOR
    CPA-ADVISOR
    Kite was 39 in November and buyout at 180 today. Stock price means little with biotechs. When company gets a bid its game over. Sgen will get a bid when Bakers want to sell. Very encouraging, that Bakers have not purchased recently. I thought they may have but was wrong to date. Glad I was wrong as a matter of fact. Advertising will easily be a billion dollar drug. Sgen pipeline and collaborations hold great value also. Sgen will go. Unless bakers want to hold on forever and turn it into there major biotech. I don't think that will happen and a sale is being set up. Good luck longs.
  • P
    P
    P
    Finally. BB's won't take less than $100/share, if they choose to sell at all
  • A
    Anonymous
    Anonymous
    SGEN goes up on high volume today. Anyone cares to share?

    Thanks!
    Nhan
  • A
    Anonymous
    Anonymous
    Guess Gilead is not buying SGEN. Shucks!!
    Kool
  • r
    ron
    ron
    Hope this rockets 🚀 up to 60 so I can sell some and buy myself a Rolex GMT!
  • A
    Anonymous
    Anonymous
    Closed at HOD on heavy volume (over 200K shares traded in last 20 i. Did something interesting leak out or is this a bear trap?
    Hope to hear some positive developments for CD33 trials. I know that hope springs eternal Paladin.
    Kool
  • T
    Trent
    Trent
    Any company wanting to buy SGEN would be wise to do it before adcetris label gets expanded!!
  • A
    Anonymous
    Anonymous
    SGEN's investment in IMMU is doing quite well at this point in time.
    Paladin
  • B
    BlockbusterPicks
    BlockbusterPicks

    SNOA (MC $23 M) (Cash $13 M) Shares Out: 4.3 M / 17 FDA approved products some of them are in early launch phase plus additional Product launches expected within 6 months / Profitable in 2018 = 1000%+ UPSIDE POTENTIAL..GLTA

    Sonoma Pharma (Nasdaq: SNOA)

    Market Cap: 22.1 Million
    Cash: $12.6 Million
    Price: $5.15

    Shares Out : 4.3 Million

    Presentation
    http://ir.sonomapharma.com/common/download/download.cfm?companyid=ocls&fileid=945547&filekey=F57B6874-6CD1-4205-A160-8E08BBB7A928&filename=SonomaPharma_Investor_presentation_13June2017.pdf

    Fact Sheet
    http://files.shareholder.com/downloads/OCLS/4977255852x0x231236/39d834a3-8462-40ee-8650-e0945b6facd5/Sonoma_Fact_Sheet.pdf

    Driving to commercial EBITDAS breakeven, without dilution

    Grow current product portfolio with all sales people

    •Alevicyn HydroGel, Dermal Spray & Spray Gel for atopic dermatitis & dermal procedures •Celacyn for scar treatment
    •Mondoxyne for severe acne –launched late 2015
    •Ceramax for skin repair in atopic dermatitis–launched in April 2016
    •SebuDerm for seborrhea dermatitis –launched in November 2016

    Launch 3 New Products –our product pipeline –one every other quarter

    •Launching Loyon–Fall 2017
    •Ceramax in foam and gel forms –Q4 2017 & Q1 2018

    Launch and Grow New and Current Products: During fiscal year 2017, we launched four new dermatology products, including SebuDerm™, Ceramax™, Lasercyn™ Gel and Lasercyn™ Dermal Spray, bringing us to a total of eight dermatology products for the treatment of atopic and seborrheic dermatitis, scar management, surgical procedures, severe acne and “state of the art” skin repair technology. We also obtained three new FDA clearances, now totaling 16 overall. Our strong intellectual property portfolio consists of 63 issued patents and 33 patent applications pending.

    We plan to launch our new FDA approved product Loyon® (a skin descaler currently marketed in Europe) in the upcoming months and have a strong product pipeline of several product line improvements, including a line extension of Ceramax™. All in all, we believe this could possibly be our best product line of new FDA approved dermatology and skincare products yet, and we believe our innovation plan will help lead us to profitability.

  • M
    Maurizio
    Maurizio
    Have we finally bottomed???!!!
  • G
    GreatDayStockGuruInCA
    GreatDayStockGuruInCA
    Eyeing SGEN here near 52 week LOW! Also like ACRX, with an Oct 12th FDA APPROVAL date for Dsuvia, with peak U.S. sales estimated at over $1 billion dollars...